A citation-based method for searching scientific literature

Stephen L Hauser, Emmanuelle Waubant, Douglas L Arnold, Timothy Vollmer, Jack Antel, Robert J Fox, Amit Bar-Or, Michael Panzara, Neena Sarkar, Sunil Agarwal, Annette Langer-Gould, Craig H Smith. N Engl J Med 2008
Times Cited: 1644







List of co-cited articles
907 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj,[...]. N Engl J Med 2017
861
41

Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Jeffrey A Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jerome de Seze, David Leppert, Xavier Montalban,[...]. N Engl J Med 2020
169
32

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer,[...]. N Engl J Med 2017
892
32

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Kathleen Hawker, Paul O'Connor, Mark S Freedman, Peter A Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch,[...]. Ann Neurol 2009
604
30

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg,[...]. Neurology 2016
200
25

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Roberta Magliozzi, Owain Howell, Abhilash Vora, Barbara Serafini, Richard Nicholas, Maria Puopolo, Richard Reynolds, Francesca Aloisi. Brain 2007
916
21

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or, Peter A J Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J Fox, Michael Panzara,[...]. Ann Neurol 2008
379
21

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen,[...]. Lancet 2011
482
20

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Mathias Granqvist, Malin Boremalm, Amyar Poorghobad, Anders Svenningsson, Jonatan Salzer, Thomas Frisell, Fredrik Piehl. JAMA Neurol 2018
116
16

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.
Ivan Jelcic, Faiez Al Nimer, Jian Wang, Verena Lentsch, Raquel Planas, Ilijas Jelcic, Aleksandar Madjovski, Sabrina Ruhrmann, Wolfgang Faigle, Katrin Frauenknecht,[...]. Cell 2018
227
16

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Edward Fox, Amy E Lovett-Racke, Matthew Gormley, Yue Liu, Maria Petracca, Sirio Cocozza, Richard Shubin, Sibyl Wray, Michael S Weiss, Jenna A Bosco,[...]. Mult Scler 2021
44
36

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman,[...]. Lancet Neurol 2018
16

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
Amit Bar-Or, Lama Fawaz, Boli Fan, Peter J Darlington, Aja Rieger, Christine Ghorayeb, Peter A Calabresi, Emmanuelle Waubant, Stephen L Hauser, Jiameng Zhang,[...]. Ann Neurol 2010
331
15

Immunopathology of multiple sclerosis.
Calliope A Dendrou, Lars Fugger, Manuel A Friese. Nat Rev Immunol 2015
15

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Christian Klein, Alfred Lammens, Wolfgang Schäfer, Guy Georges, Manfred Schwaiger, Ekkehard Mössner, Karl-Peter Hopfner, Pablo Umaña, Gerhard Niederfellner. MAbs 2013
197
15

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson,[...]. JAMA Neurol 2020
240
14

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.
Barbara Serafini, Barbara Rosicarelli, Roberta Magliozzi, Egidio Stigliano, Francesca Aloisi. Brain Pathol 2004
810
14

Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Rui Li, Ayman Rezk, Yusei Miyazaki, Ellen Hilgenberg, Hanane Touil, Ping Shen, Craig S Moore, Laure Michel, Faisal Althekair, Sathy Rajasekharan,[...]. Sci Transl Med 2015
249
14

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Chris H Polman, Paul W O'Connor, Eva Havrdova, Michael Hutchinson, Ludwig Kappos, David H Miller, J Theodore Phillips, Fred D Lublin, Gavin Giovannoni, Andrzej Wajgt,[...]. N Engl J Med 2006
14

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Amit Bar-Or, Richard A Grove, Daren J Austin, Jerry M Tolson, Susan A VanMeter, Eric W Lewis, Frederick J Derosier, Monica C Lopez, Sarah T Kavanagh, Aaron E Miller,[...]. Neurology 2018
97
13

Defining the clinical course of multiple sclerosis: the 2013 revisions.
Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof,[...]. Neurology 2014
13

Multiple Sclerosis.
Daniel S Reich, Claudia F Lucchinetti, Peter A Calabresi. N Engl J Med 2018
987
13

Reassessing B cell contributions in multiple sclerosis.
Rui Li, Kristina R Patterson, Amit Bar-Or. Nat Immunol 2018
187
12

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Per S Sorensen, Steen Lisby, Richard Grove, Frederick Derosier, Steve Shackelford, Eva Havrdova, Jelena Drulovic, Massimo Filippi. Neurology 2014
191
12

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.
Owain W Howell, Cheryl A Reeves, Richard Nicholas, Daniele Carassiti, Bishan Radotra, Steve M Gentleman, Barbara Serafini, Francesca Aloisi, Federico Roncaroli, Roberta Magliozzi,[...]. Brain 2011
510
12

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Chris H Polman, Stephen C Reingold, Brenda Banwell, Michel Clanet, Jeffrey A Cohen, Massimo Filippi, Kazuo Fujihara, Eva Havrdova, Michael Hutchinson, Ludwig Kappos,[...]. Ann Neurol 2011
12

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher,[...]. Lancet 2012
795
12

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.
C Lucchinetti, W Brück, J Parisi, B Scheithauer, M Rodriguez, H Lassmann. Ann Neurol 2000
11

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Amit Bar-Or, Jonathan C Calkwood, Cathy Chognot, Joanna Evershed, Edward J Fox, Ann Herman, Marianna Manfrini, John McNamara, Derrick S Robertson, Daniela Stokmaier,[...]. Neurology 2020
191
11

B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers.
Jamie van Langelaar, Liza Rijvers, Joost Smolders, Marvin M van Luijn. Front Immunol 2020
74
14

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.
Jeffrey M Gelfand, Bruce A C Cree, Stephen L Hauser. Neurotherapeutics 2017
89
11

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
R T Naismith, L Piccio, J A Lyons, J Lauber, N T Tutlam, B J Parks, K Trinkaus, S K Song, A H Cross. Neurology 2010
156
10

B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.
Maria T Cencioni, Miriam Mattoscio, Roberta Magliozzi, Amit Bar-Or, Paolo A Muraro. Nat Rev Neurol 2021
44
22

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
Barbara Scotti, Giulio Disanto, Rosaria Sacco, Marilu' Guigli, Chiara Zecca, Claudio Gobbi. PLoS One 2018
32
28

Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
Arumugam Palanichamy, Sarah Jahn, Dorothee Nickles, Mia Derstine, Aya Abounasr, Stephen L Hauser, Sergio E Baranzini, David Leppert, H-Christian von Büdingen. J Immunol 2014
162
9

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
Pierre de Flon, Martin Gunnarsson, Katarina Laurell, Lars Söderström, Richard Birgander, Thomas Lindqvist, Wolfgang Krauss, Ann Dring, Joakim Bergman, Peter Sundström,[...]. Neurology 2016
63
14

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer, Anna Björck, Markus Axelsson, Clas Malmeström, Katharina Fink, Jan Lycke,[...]. Ann Neurol 2016
150
9

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Laura Piccio, Robert T Naismith, Kathryn Trinkaus, Robyn S Klein, Becky J Parks, Jeri A Lyons, Anne H Cross. Arch Neurol 2010
172
9

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.
Martin Duddy, Masaaki Niino, Femina Adatia, Sherry Hebert, Mark Freedman, Harry Atkins, Ho Jin Kim, Amit Bar-Or. J Immunol 2007
454
9

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Maria P Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Capobianco, Maria Trojano,[...]. Ann Neurol 2021
242
9

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Xavier Montalban, Douglas L Arnold, Martin S Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Jonathan Willmer, Emily C Martin, Fernando Dangond, Sana Syed, Jerry S Wolinsky. N Engl J Med 2019
139
9

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Jerry S Wolinsky, Douglas L Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalban, Robert T Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter,[...]. Lancet Neurol 2020
50
18

Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis.
Birgit Obermeier, Reinhard Mentele, Joachim Malotka, Josef Kellermann, Tania Kümpfel, Hartmut Wekerle, Friedrich Lottspeich, Reinhard Hohlfeld, Klaus Dornmair. Nat Med 2008
195
9

The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.
Joana Machado-Santos, Etsuji Saji, Anna R Tröscher, Manuela Paunovic, Roland Liblau, Galina Gabriely, Christian G Bien, Jan Bauer, Hans Lassmann. Brain 2018
232
9

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Alasdair J Coles, Cary L Twyman, Douglas L Arnold, Jeffrey A Cohen, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner,[...]. Lancet 2012
786
9

B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.
Joel N H Stern, Gur Yaari, Jason A Vander Heiden, George Church, William F Donahue, Rogier Q Hintzen, Anita J Huttner, Jon D Laman, Rashed M Nagra, Alyssa Nylander,[...]. Sci Transl Med 2014
292
9

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.
Despoina Florou, Maria Katsara, Jack Feehan, Efthimios Dardiotis, Vasso Apostolopoulos. Brain Sci 2020
25
36

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
Kjetil Bjornevik, Marianna Cortese, Brian C Healy, Jens Kuhle, Michael J Mina, Yumei Leng, Stephen J Elledge, David W Niebuhr, Ann I Scher, Kassandra L Munger,[...]. Science 2022
266
9

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Bassem I Yamout, Nabil K El-Ayoubi, Johny Nicolas, Yehya El Kouzi, Samia J Khoury, Maya M Zeineddine. J Immunol Res 2018
31
25

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.
David Baker, Monica Marta, Gareth Pryce, Gavin Giovannoni, Klaus Schmierer. EBioMedicine 2017
156
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.